Want to see JBIO full AI Analyst Report?
JBIO Stock Chart & Stats
$20.08
$0.42(2.09%)
At close: 4:00 PM EDT
$20.08
$0.42(2.09%)
Day’s Range― - ―
52-Week Range$6.67 - $28.00
Previous CloseN/A
Volume1.06M
Average Volume (3M)1.18M
Market Cap
$1.57B
Enterprise Value$895.97
Total Cash (Recent Filing)$461.20M
Total Debt (Recent Filing)$628.00K
Price to Earnings (P/E)―
Beta0.20
Next Earnings
Nov 16, 2026EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.55
Shares Outstanding63,597,385
10 Day Avg. Volume894,398
30 Day Avg. Volume1,180,703
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio-5.10
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.05
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$50.13Price Target Upside149.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.62
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Strong CapitalizationJade’s minimal debt and large equity base provide durable financial flexibility to fund multi-year clinical programs without immediate refinancing pressure. Low leverage reduces default risk, supports investment in R&D and manufacturing scale-up, and preserves strategic optionality as trials advance.
Material Equity Financing Bolstering RunwayThe recent underwritten offering meaningfully increases cash available for clinical trials, preclinical work, manufacturing and R&D. That capital reduces short-term financing dependence, supports planned Phase 2/3 activity, and lowers execution risk while the company advances late-stage programs.
Positive Phase 1 JADE101 Data And Accelerated PlanRobust PD, tolerability and extended half-life signal potential best-in-class positioning in IgA nephropathy; accelerated movement into Phase 2 and planned Phase 3 establishes a clear, time-bound development path that can materially de-risk the program if confirmatory efficacy is shown.
Bears Say
Pre-revenue With Widening Net LossesJade remains a development-stage, pre-revenue company with materially negative and widening net losses. Without commercial revenue, the business depends on capital markets and milestone receipts; persistent losses can erode equity and limit strategic flexibility if clinical timelines slip or costs rise.
Accelerating Negative Operating And Free Cash FlowSustained and growing cash burn is a structural constraint: it necessitates further financing to complete registrational studies and commercialization prep. Ongoing negative cash flow increases dilution risk, may force milestone-linked financing, and limits capacity to pursue parallel programs without additional capital.
Milestone And Royalty Obligations From Paragon LicenseThe exclusive antibody license secures pipeline optionality but creates contingent cash and royalty obligations that reduce future product-level margins. If programs succeed, milestone and royalty payments will meaningfully affect net economics and could constrain capital available for other programs or commercialization.
Jade Biosciences News
JBIO FAQ
What was Jade Biosciences, Inc.’s price range in the past 12 months?
Jade Biosciences, Inc. lowest stock price was $6.67 and its highest was $28.00 in the past 12 months.
What is Jade Biosciences, Inc.’s market cap?
Jade Biosciences, Inc.’s market cap is $1.57B.
When is Jade Biosciences, Inc.’s upcoming earnings report date?
Jade Biosciences, Inc.’s upcoming earnings report date is Nov 16, 2026 which is in 91 days.
How were Jade Biosciences, Inc.’s earnings last quarter?
Jade Biosciences, Inc. released its earnings results on Aug 10, 2026. The company reported -$0.76 earnings per share for the quarter, missing the consensus estimate of -$0.636 by -$0.124.
Is Jade Biosciences, Inc. overvalued?
According to Wall Street analysts Jade Biosciences, Inc.’s price is currently Undervalued.
Does Jade Biosciences, Inc. pay dividends?
Jade Biosciences, Inc. pays a Notavailable dividend of $2.4 which represents an annual dividend yield of N/A. See more information on Jade Biosciences, Inc. dividends here
What is Jade Biosciences, Inc.’s EPS estimate?
Jade Biosciences, Inc.’s EPS estimate is -0.73.
How many shares outstanding does Jade Biosciences, Inc. have?
Jade Biosciences, Inc. has 63,597,385 shares outstanding.
What happened to Jade Biosciences, Inc.’s price movement after its last earnings report?
Jade Biosciences, Inc. reported an EPS of -$0.76 in its last earnings report, missing expectations of -$0.636. Following the earnings report the stock price went down -1.047%.
Which hedge fund is a major shareholder of Jade Biosciences, Inc.?
Currently, no hedge funds are holding shares in JBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jade Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.13 (149.63% Upside)
$50.13 (149.63% Upside)
Blogger Sentiment
Bullish
JBIO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 333.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 13.2%
Last 30 Days ▲ 11.8%
Last 30 Days ▲ 11.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
140.94%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
110.79%
Trailing 12-Months
Company Description
Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specifically targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway, aiming to treat immunoglobulin A (IgA) nephropathy. Clinical trials for JADE-001 are slated to commence in the latter half of 2025, with initial results projected for the first half of 2026. Beyond this lead asset, the company's robust pipeline includes two preclinical antibody programs, JADE-002 and JADE-003.
JBIO Stock 12 Month Forecast
Average Price Target
$50.13
▲(149.63% Upside)
Technical Analysis
Ownership Overview
8.01% Insiders
13.47% Mutual Funds
54.80% Other Institutional Investors
14.17% Public Companies and
Individual Investors